GlassScriptPhysician profile
Julie A Sawade
NPI 1285847525
$1,999.46
in general payments reported to CMS, 2019-2025
26 companies · $33.23 in 2025
The $33.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $389 · 2021: $486 · 2022: $261 · 2023: $360 · 2024: $138 · 2025: $33.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $502.41 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $203.68 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $175.09 | 2019-2023 | |
| Abbvie INC. | $151.39 | 2021-2022 | |
| Lilly USA, LLC | $144.26 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $93.64 | 2020-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.35 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $73.85 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $55.07 | 2019-2023 | |
| Allergan, INC. | $51.59 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $49.18 | 2022-2023 | Seglentis, Livalo |
| Grifols USA, LLC | $46.73 | 2019-2020 | |
| Glaxosmithkline, LLC. | $44.85 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $44.75 | 2019-2023 | |
| Amgen INC. | $42.25 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $41.98 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $35.51 | 2021 | |
| Indivior INC. | $28.46 | 2021-2022 | |
| Abbott Laboratories | $19.35 | 2024 | Proclaim |
| Biohaven Pharmaceutical Holding Company LTD. | $18.10 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.56 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $15.83 | 2024 | Belbuca |
| Orexo US, INC. | $15.26 | 2023 | Zubsolv |
| Bayer Healthcare Pharmaceuticals INC. | $15.06 | 2023 | |
| Merck Sharp & Dohme LLC | $13.40 | 2019 | |
| Harmony Biosciences LLC | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Sawade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.